Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11419682 | 0.85 | DAGLA (0.50) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL16710283 | 0.85 | DAGLA (0.50) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL17253394 | 0.83 | DAGLA (0.40) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL30844009 | 0.82 | TSHR (0.38) | ALDH1A1 | |
| SCHEMBL17253455 | 0.80 | DAGLA (0.45) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL17253444 | 0.80 | DAGLA (0.45) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL28826749 | 0.75 | DAGLA (0.43) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL12833418 | 0.75 | FFAR4 (0.71) | FFAR4FFAR1GPR84TBXA2RPTGFR | |
| SCHEMBL20610777 | 0.72 | FFAR1 (0.47) | DAGLAFFAR4FFAR1GPR84TBXA2R | |
| SCHEMBL20610778 | 0.72 | FFAR1 (0.47) | DAGLAFFAR4FFAR1GPR84TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073301-A1 | CARDANOL GLYCIDYL ETHER DERIVATIVES | OLEOTEK (CA) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073301-A1 | CARDANOL GLYCIDYL ETHER DERIVATIVES | CD14, GYPA, ALG8 | DAGLA 534/4885FFAR4 1017/4885FFAR1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.